Saturday, October 14, 2017 11:17:13 AM
VB-111 Ph2 results:
54% - 57% @ 52 weeks*
50% @ 59 weeks
Avastin's historical data suggests:
50% @ 34 weeks**
28% @ 52 weeks ***
* Both 54% and 57% are used in presentation. (Slide 12 & 22, Sept17 presentation)
**I took average after removing the best & worst data points from historical control data. (Slide 21, Sept17 presentation)
*** I took the average after removing the best & worst data points from historical control data. (Slide 22, Sept17 presentation)
Now let's look at your assumption, Oren. If Avastin and Avastin+VB-111 are performing similarly at mOS, then that would imply either of these two scenarios:
Scenario 1: Avastin is MAJORLY over-performing.
This assumes no change in VB-111 performance, so Avastin alone needs a 52-week survival around 54-57%. I have to hope this high unlikely event did not happen.
Scenario 2: VB-111 in combo with Avastin is MAJORLY under-performing.
This assumes no change in Avastin performance, so Avastin+VB111 must have a mOS of closer to 34 weeks. Then, your assumption about 12-month survival being different between treatment and control would then require the surviving Avastin patients continues to diminish to 28% @ 52 weeks. However, the long-tail of survival due to VB111 will manifest as a survival rate somewhere between 35-50% @ 52 weeks for Avastin+VB111.
This is not out of the realm of possibility. I would be a tougher road to approval, because things would become a bit more subjective. Dror in recent talks has mentioned looking beyond just mOS (ie. looking for long-term survival relative to what is known with other IO agents, correlating response to initial tumor size, etc).
Oren, is Scenario 2 what you are saying is currently happening?
Given the rigor of Ph2 trials and that it did include VB111+Avastin, I would like to think that VB111+Avastin is performing closer to what was observed in Ph2. And so I would expect both the mOS and long-term survival to lean significantly in favor of VB111.
Recent VBLT News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 08:05:19 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/29/2024 08:06:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:34:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:31:04 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/09/2024 08:01:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 09:20:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 11:40:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 08:05:36 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/01/2024 09:19:40 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/20/2024 09:01:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:18:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:17:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:12:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:07:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:06:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:04:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:30:44 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/19/2024 08:56:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/12/2024 12:44:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/11/2024 09:00:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2024 09:20:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2024 04:15:14 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2024 01:00:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 01:15:22 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM